Which disease-relevant molecular pathways and gene-network modules most plausibly drive Pancreatic ductal adenocarcinoma initiation and progression, and what causal experiments (e.g., perturbation, si

Pancreatic ductal adenocarcinoma (PDAC) is driven by an evolutionary trajectory of genetic mutations—primarily involving the KRAS, TP53, CDKN2A, and SMAD4 "big four"—and orchestrated by complex signaling networks within a desmoplastic tumor microenvironment (TME) (PMID: 28810144, PMID: 33676749). Current evidence emphasizes that PDAC initiation and progression are not solely epithelial events but result from niche programming, metabolic shifts, and immune evasion modules (PMID: 41634803, PMID: 38154529).

Disease-Relevant Molecular Pathways and Gene-Network Modules

1. The Initiation Module: Oncogenic KRAS and Niche Preparation

• Oncogenic Signaling: Activating mutations in KRAS (predominantly G12D and G12V) are found in >90% of cases and act as the initiating event in pancreatic intraepithelial neoplasia (PanIN) (PMID: 33676749, PMID: 41712870).
• Acinar-to-Ductal Metaplasia (ADM): Inflammatory macrophages secrete factors like TNFα, IL-6, and RANTES that generate mitochondrial reactive oxygen species (ROS) in acinar cells, driving their transdifferentiation to a duct-like progenitor state (PMID: 38576613).
• Epithelial Secretome and Niche Preparation: Early oncogenic KRAS G12D expression activates a TNF-NF-κB signaling axis. This epithelial-derived secretome primes the niche by activating pancreatic stellate cells (PaSCs) toward a pro-tumorigenic inflammatory fibroblast (iCAF) phenotype and creating a "T-cell shield" that prevents immune infiltration before invasive carcinoma onset (PMID: 41634803).

2. The Progression and Heterogeneity Module: Subtypes and CAF Transitions

• Molecular Subtyping: PDAC progresses through two major transcriptional states: Classical (associated with GATA6 expression and ductal differentiation) and Basal-like (associated with TP53 mutations, squamous features, and worse prognosis) (PMID: 34465850, PMID: 41727227).
• CAF-Epithelial Crosstalk: Cancer-associated fibroblasts (CAFs) actively induce ADM and tumor initiation through a novel LAMA5/ITGA4/STAT3 axis, where fibroblast-derived Laminin α5 interacts with Integrin α4 on acinar cells to trigger ductal reprogramming (PMID: 38154529).
• CAF Diversity: Spatial single-cell profiling identifies myofibroblastic (myCAF), inflammatory (iCAF), and antigen-presenting (apCAF) subtypes existing as early as the PanIN stage, suggesting TME remodeling is a sustained driver of progression (PMID: 39116880).

3. The Immune Evasion Module: cGAS-STING and Myeloid Suppression

• STING Suppression: The transmembrane protein UNC93B1 is overexpressed in PDAC and promotes progression by binding to STING and facilitating its autophagic-lysosomal degradation, thereby dampening the cGAS-STING innate immune response (PMID: 41716413).
• Microbiome-Induced Inflammation: Specific microbial taxa (e.g., Pseudomonas, Acinetobacter) are enriched in aggressive basal-like tumors, where they correlate with activated KRAS signaling and the recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs) (PMID: 34465850, PMID: 31398337).

Prioritized Causal Experiments to Validate Mechanism

To move beyond association, the following experimental frameworks are prioritized based on established human and murine models:

1. Human Stem Cell-Derived Organoid (PDLO) Systems

• Experiment: Utilize human induced pluripotent stem cell (hiPSC)-derived pancreatic duct-like organoids (PDLOs) with doxycycline-inducible oncogenic KRAS G12D (PMID: 41634803).
• Validation: Perform shRNA/CRISPR perturbation of nominated secretome factors (e.g., TNFα, LAMA5) in epithelial cells and assess the impact on T-cell migration and stellate cell activation in organoid-niche co-cultures (PMID: 41634803, PMID: 38154529).

2. Functional Multi-Omics and Rescue Assays

• Experiment: Integrate single-cell RNA-seq (scRNA-seq) with GWAS and proteomics to identify "hub" regulators like UNC93B1 or PCDH1 (PMID: 41716413, PMID: 41602375).
• Validation: Execute pharmacological rescue experiments. For instance, treat UNC93B1-knockdown cells with the STING inhibitor H-151 to determine if the loss of malignant phenotype is specifically mediated by hyperactivated STING signaling (PMID: 41716413). Similarly, use IGF-1 to rescue the proliferative deficits of PCDH1-depleted cells to validate the PI3K-Akt axis dependence (PMID: 41602375).

3. Spatial Single-Cell Validation

• Experiment: Deploy Xenium in situ RNA hybridization and Imaging Mass Cytometry (IMC) on human PanIN and PDAC specimens (PMID: 39116880).
• Validation: Map the physical proximity of apCAFs (MHCII+/CD45-) to CD4+ T-cells to validate the mechanism of antigen-specific regulatory T-cell induction in the early pre-cancerous niche (PMID: 39116880).

4. Microbiome Causal Transfer (FMT)

• Experiment: Perform Fecal Microbiota Transplant (FMT) from long-term PDAC survivors (LTS) versus short-term survivors (STS) into antibiotic-ablated tumor-bearing mice (PMID: 31398337).
• Validation: Assess if the LTS-derived microbiome induces T-cell-dependent tumor regression and increased IFN-γ/IL-2 serum levels, providing causal proof that microbial diversity modulates the host immune response to control PDAC natural history (PMID: 31398337).

Evidence Quality and Limitations

• Quality: Strong regarding canonical drivers (KRAS/TP53) and emerging niche mechanisms (organoid/co-culture models). Moderate for specific microbial "oncomicrobes" due to low-biomass contamination risks (PMID: 41658610).
• Limitations: Many mechanistic insights regarding ADM and early niche preparation rely on rodent models or 2D/3D in vitro systems that may not fully recapitulate human fibrosis or systemic immune responses (PMID: 41749827, PMID: 41530855). Clinical translation of these findings into interception strategies remains speculative without prospective human validation trials (PMID: 41731281).